140 related articles for article (PubMed ID: 12188033)
21. BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor.
Wada Y; Yagihashi A; Terasawa K; Miyao N; Hirata K; Cicciarelli J; Iwaki Y
Artif Organs; 1996 Aug; 20(8):849-52. PubMed ID: 8853794
[TBL] [Abstract][Full Text] [Related]
22. Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primates.
Kilpatrick JM; Morris PE; Serota DG; Phillips D; Moore DR; Bennett JC; Babu YS
Int Immunopharmacol; 2003 Apr; 3(4):541-8. PubMed ID: 12689658
[TBL] [Abstract][Full Text] [Related]
23. Nucleoside-mediated mitigation of 5-fluorouracil-induced toxicity in synchronized murine erythroleukemic cells.
Elstein KH; Mole ML; Setzer RW; Zucker RM; Kavlock RJ; Rogers JM; Lau C
Toxicol Appl Pharmacol; 1997 Sep; 146(1):29-39. PubMed ID: 9299594
[TBL] [Abstract][Full Text] [Related]
24. Biochemical and pharmacological properties of CI-972, a novel 9-deazaguanine analog purine nucleoside phosphorylase (PNP) inhibitor.
Gilbertsen RB; Dong MK; Wilburn DJ; Kossarek LM; Sircar JC; Kostlan CR; Conroy MC
Adv Exp Med Biol; 1991; 309A():41-4. PubMed ID: 1789255
[TBL] [Abstract][Full Text] [Related]
25. Functional and mechanistic studies on the toxicity of deoxyguanosine for the in vitro proliferation and differentiation of human peripheral blood B lymphocytes.
Scharenberg JG; Spaapen LJ; Rijkers GT; Duran M; Staal GE; Zegers BJ
Eur J Immunol; 1986 Apr; 16(4):381-7. PubMed ID: 3084280
[TBL] [Abstract][Full Text] [Related]
26. The mechanism of inhibition and "reversal" of mitogen-induced lymphocyte activation in a model of purine-nucleoside phosphorylase deficiency.
Albert D; Bluestein HG; Willis RC; Nette K; Seegmiller JE
Cell Immunol; 1984 Jul; 86(2):501-9. PubMed ID: 6428752
[TBL] [Abstract][Full Text] [Related]
27. SAMHD1 Limits the Efficacy of Forodesine in Leukemia by Protecting Cells against the Cytotoxicity of dGTP.
Davenne T; Klintman J; Sharma S; Rigby RE; Blest HTW; Cursi C; Bridgeman A; Dadonaite B; De Keersmaecker K; Hillmen P; Chabes A; Schuh A; Rehwinkel J
Cell Rep; 2020 May; 31(6):107640. PubMed ID: 32402273
[TBL] [Abstract][Full Text] [Related]
28. Different pathways for deoxyguanosine toxicity in T-lymphocytes of various developmental stages.
Scharenberg JG; Rijkers GT; Spaapen LJ; Toebes EA; Rijksen G; Duran M; Staal GE; Zegers BJ
Int J Immunopharmacol; 1988; 10(6):675-86. PubMed ID: 2974022
[TBL] [Abstract][Full Text] [Related]
29. Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor.
Gilbertsen RB; Scott ME; Dong MK; Kossarek LM; Bennett MK; Schrier DJ; Sircar JC
Agents Actions; 1987 Aug; 21(3-4):272-4. PubMed ID: 3120507
[TBL] [Abstract][Full Text] [Related]
30. Synergistic inhibition of human leukemia cell growth by deoxyguanosine and 1-beta-D-arabinofuranosylcytosine.
Akman SA; Ross DD; Joneckis CC; Fox BM; Bachur NR
Biochem Pharmacol; 1984 Apr; 33(7):1059-63. PubMed ID: 6712715
[TBL] [Abstract][Full Text] [Related]
31. A purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells.
Posmantur R; Wang KK; Nath R; Gilbertsen RB
Immunopharmacology; 1997 Oct; 37(2-3):231-44. PubMed ID: 9403342
[TBL] [Abstract][Full Text] [Related]
32. The effect of deoxyguanosine on human lymphocyte function. II. Analysis of the interference with B lymphocyte differentiation in vitro.
Spaapen LJ; Rijkers GT; Staal GE; Rijksen G; Duran M; Stoop JW; Zegers BJ
J Immunol; 1984 May; 132(5):2318-23. PubMed ID: 6425400
[TBL] [Abstract][Full Text] [Related]
33. Selective in vitro inhibition of human MOLT-4 T lymphoblasts by the novel purine nucleoside phosphorylase inhibitor, CI-972.
Gilbertsen RB; Dong MK; Kossarek LM; Sircar JC; Kostlan CR; Conroy MC
Biochem Biophys Res Commun; 1991 Aug; 178(3):1351-8. PubMed ID: 1908235
[TBL] [Abstract][Full Text] [Related]
34. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
Furman RR; Hoelzer D
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
[TBL] [Abstract][Full Text] [Related]
35. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Balakrishnan K; Verma D; O'Brien S; Kilpatrick JM; Chen Y; Tyler BF; Bickel S; Bantia S; Keating MJ; Kantarjian H; Gandhi V; Ravandi F
Blood; 2010 Aug; 116(6):886-92. PubMed ID: 20427701
[TBL] [Abstract][Full Text] [Related]
36. Deoxyribonucleoside triphosphate metabolism and the mammalian cell cycle. Effects of hydroxyurea on mutant and wild-type mouse S49 T-lymphoma cells.
Eriksson S; Skog S; Tribukait B; Wallström B
Exp Cell Res; 1987 Jan; 168(1):79-88. PubMed ID: 3096753
[TBL] [Abstract][Full Text] [Related]
37. Deoxyadenosine triphosphate as a mediator of deoxyguanosine toxicity in cultured T lymphoblasts.
Mann GJ; Fox RM
J Clin Invest; 1986 Nov; 78(5):1261-9. PubMed ID: 3490493
[TBL] [Abstract][Full Text] [Related]
38. Molecular analysis of mutations in the hprt gene of V79 hamster fibroblasts: effects of imbalances in the dCTP, dGTP and dTTP pools.
Darè E; Zhang LH; Jenssen D; Bianchi V
J Mol Biol; 1995 Oct; 252(5):514-21. PubMed ID: 7563070
[TBL] [Abstract][Full Text] [Related]
39. Regulatory effects of deoxyribonucleosides on the activity of 5-methoxymethyl-2'-deoxycytidine: modulation of antiherpes activity by deoxyguanosine and tetrahydrodeoxyuridine.
Aduma PJ; Gupta SV; Stuart AL; Tourigny G
Antiviral Res; 1991 May; 15(4):301-13. PubMed ID: 1659312
[TBL] [Abstract][Full Text] [Related]
40. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
